A stable c-Met antibody-drug conjugate (c-Met ADC) formulation and use thereof in medicine. Said formulation comprises c-Met ADC, a buffer, and can also comprise at least one stabilizer, and optionally a surfactant. The c-Met ADC formulation of the present invention can effectively inhibit the aggregation and isomerization of antibodies, and prevent the degradation of an antibody product therein, being a stable injectable pharmaceutical formulation.